<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">NaHCO3 enhances the antitumor activities of cytokine-induced killer cells against hepatocellular carcinoma HepG2 cells</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Spandidos Publications</publisher>
				<availability status="unknown"><p>Copyright Spandidos Publications</p>
				</availability>
				<date type="published" when="2016-09-09">2016-09-09</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ya</forename><forename type="middle">Hong</forename><surname>Yuan</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chun</forename><forename type="middle">Fang</forename><surname>Zhou</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jiang</forename><surname>Yuan</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Li</forename><surname>Liu</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xing</forename><forename type="middle">Rong</forename><surname>Guo</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Hubei Key Laboratory of Embryonic Stem Cell Research</orgName>
								<orgName type="institution">Taihe Hospital</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiao</forename><forename type="middle">Li</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Hubei Key Laboratory of Embryonic Stem Cell Research</orgName>
								<orgName type="institution">Taihe Hospital</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yan</forename><surname>Ding</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Hubei Key Laboratory of Embryonic Stem Cell Research</orgName>
								<orgName type="institution">Taihe Hospital</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiao</forename><forename type="middle">Nan</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Hubei Key Laboratory of Embryonic Stem Cell Research</orgName>
								<orgName type="institution">Taihe Hospital</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>Professor</roleName><forename type="first">Dong</forename><forename type="middle">Sheng</forename><surname>Li</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Han</forename><forename type="middle">Jun</forename><surname>Tu</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Hubei Key Laboratory of Embryonic Stem Cell Research</orgName>
								<orgName type="institution">Taihe Hospital</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="laboratory">Laboratory of Embryonic Stem Cell Research</orgName>
								<orgName type="institution" key="instit1">Taihe Hospital</orgName>
								<orgName type="institution" key="instit2">Hubei University of Medicine</orgName>
								<address>
									<addrLine>Renmin Road 32</addrLine>
									<postCode>442000</postCode>
									<settlement>Shiyan</settlement>
									<region>Hubei</region>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">NaHCO3 enhances the antitumor activities of cytokine-induced killer cells against hepatocellular carcinoma HepG2 cells</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Oncology Letters</title>
						<idno type="ISSN">1792-1074</idno>
						<idno type="eISSN">1792-1082</idno>
						<imprint>
							<publisher>Spandidos Publications</publisher>
							<biblScope unit="volume">12</biblScope>
							<biblScope unit="issue">5</biblScope>
							<biblScope unit="page" from="3167" to="3174"/>
							<date type="published" when="2016-09-09" />
						</imprint>
					</monogr>
					<idno type="DOI">10.3892/ol.2016.5112</idno>
					<idno type="PMID">27899977</idno>
					<idno type="PMCID">PMC5103916</idno>
					<ptr type="open-access" target="http://www.spandidos-publications.com/10.3892/ol.2016.5112/download" />
					<note type="submission">Received May 11, 2015; Accepted July 28, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-14T00:25+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>NaHCO 3</term>
					<term>cytokine-induced killer cells</term>
					<term>HepG2</term>
					<term>extracellular pH</term>
					<term>acidic microenvironment</term>
				</keywords>
			</textClass>
			<abstract>
				<p>The extracellular pH is lower inside solid tumors than in normal tissue. The acidic environment inhibits the cytotoxicity of lymphocytes in vitro and promotes tumor cell invasion. In the present study, both in vitro and in vivo experiments were conducted to investigate how NaHCO 3 would affect the antitumor activities of cytokine-induced killer (CIK) cells against hepatocellular carcinoma (HCC) cells. For the in vitro experiments, HepG2 cells were cultured at pH 6.5 and 7.4 in the presence of CIK cells or CIK cell-conditioned medium (CM CIK). For the in vivo experiments, nude mice were xenografted with HepG2-luc cells and divided into four groups: i) CIK cells injection plus NaHCO 3 feeding; ii) CIK cells injection plus drinking water feeding; iii) normal saline injection plus NaHCO 3 feeding; and iv) normal saline injection plus drinking water feeding. The results indicated that the viability and growth rate of HepG2 cells were remarkably suppressed when co-cultured with CIK cells or CM CIK at pH 7.4 compared with those of HepG2 cells cultured under the same conditions but at pH 6.5. In the xenograft study, a marked synergistic antitumor effect of the combined therapy was observed. NaHCO 3 feeding augmented the infiltration of cluster of differentiation 3-positive T lymphocytes into the tumor mass. Taken together, these data strongly suggest that the antitumor activities of CIK cells against HepG2 cells were negatively affected by the acidic environment inside the tumors, and neutralizing the pH (for example, via NaHCO 3 administration), could therefore reduce or eliminate this influence. In addition, it should be recommended that oncologists routinely prescribe soda water to their patients, particularly during CIK cell therapy.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Hepatocellular carcinoma (HCC), the most frequent primary tumor of the liver, is one of the leading causes of cancerassociated mortality worldwide <ref type="bibr" target="#b0">(1)</ref>. Regarding treatment options for HCC, immunotherapy remains an important adjuvant treatment, despite advances in surgery, chemotherapy and radiotherapy <ref type="bibr" target="#b1">(2)</ref>. Cytokine-induced killer (CIK) cell therapy is currently one of the most commonly used immunotherapies <ref type="bibr" target="#b2">(3)</ref>. In order to improve the efficacy of CIK cell therapy, numerous strategies, including gene transfection <ref type="bibr" target="#b3">(4)</ref>, stimulation with certain growth factors (5), pretreatment with antitumor drugs <ref type="bibr" target="#b5">(6)</ref>, or combination with genetically modified dendritic cells <ref type="bibr" target="#b6">(7)</ref>, have been attempted in practice. However, a number of clinical trials of CIK cell therapies failed to demonstrate any noticeable improvement over other therapeutic regimens, neither in terms of HCC control rates nor long-term survival rates <ref type="bibr" target="#b7">(8)</ref>, suggesting that other factors, such as the environment where CIK cells are functioning, should also be considered for immunotherapies.</p><p>It has been demonstrated that the high metabolic demand of rapidly proliferating cancer cells, in conjunction with a shift toward glycolytic metabolism reflecting both tumor hypoxia and oncogene-induced changes in gene expression, leads to an often greatly increased production and extrusion of acid by cancer cells <ref type="bibr" target="#b8">(9,</ref><ref type="bibr" target="#b9">10)</ref>. Therefore, the extracellular pH (pHe) of malignant solid tumors is usually acidic, ranging from 6.5 to 6.9, whereas the pHe of normal tissues is significantly more alkaline, ranging from 7.2 to 7.5 <ref type="bibr" target="#b10">(11)</ref>. This disturbance of the acid-base balance is able to remodel various physiological functions, and results in solid tumors becoming more invasive and metastatic <ref type="bibr" target="#b11">(12)</ref>. In addition, it may also induce undesired resistance to immunotherapy <ref type="bibr" target="#b12">(13)</ref>. By contrast, inhibition of the acid extrusion of tumor cells may alleviate their resistance to immunotherapy <ref type="bibr" target="#b13">(14)</ref>. However, none of these speculations has ever been confirmed for CIK cell immunotherapy in vitro or in vivo. In the present study, the antitumor activities of CIK cells against HepG2 cells were evaluated both in vitro and in vivo under environments with acidic and alkaline pH.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head><p>Cell culture. HepG2 cells (ATCC, Manassas, VA, USA) or HepG2-luc cells (HepG2 cells stably transfected with a firefly luciferase gene), were cultured in Dulbecco's modified Eagle's medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) in an incubator at 37˚C with humidified atmosphere and 5% CO 2 in air. Cells were adapted in acidic (pH 6.5) or alkaline (pH 7.4) environments for three passages prior to be used for experiments. The pH values of the medium were accordingly adjusted with lactic acid, NaHCO 3 and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.</p><p>Preparation of CIK cells. Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood by standard Ficoll separation, as previously described <ref type="bibr" target="#b4">(5)</ref>. Human peripheral blood samples were obtained with full informed consent from patients with HCC. In total, six samples were collected between January 2014 and July 2014 at the Department of Gastroenterology of Renmin Hospital, Hubei University of Medicine (Shiyan, China). The isolated cells were resuspended in RPMI-1640 medium supplemented with 1,000 U/ml interferon (IFN)-γ (R&amp;D Systems, Inc., Minneapolis, MN, USA) and incubated at 37˚C for 24 h. Then, recombinant human interleukin (IL)-2 protein (cat. no. 202-IL-050; R&amp;D Systems, Inc.) and mouse anti-cluster of differentiation (CD)3 monoclonal antibody (cat. no. MAB100; dilution, 1:1,000; R&amp;D Systems, Inc.) were added at 500 U/ml and 50 ng/ml, respectively. Subsequently, the cells were refreshed with RPMI-1640 medium supplemented with IL-2 (500 U/ml) every other day for 10 days prior to being subjected to flow cytometry analysis.  <ref type="bibr" target="#b5">6</ref> CIK cells were harvested and washed once with phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA; Beyotime Institute of Biotechnology, Haimen, China), and resuspended in 100 µl PBS/BSA. The cells were then incubated with the above conjugated monoclonal antibodies separately for 20 min at 4 o C, washed twice with PBS and resuspended in 400 µl PBS. Flow cytometric analysis was performed with a BD FACSCalibur™ flow cytometer (BD Biosciences), and the data were analyzed using the WinMDI software, version 2.9 (The Scripps Research Institute, La Jolla, CA, USA). The dead cells and debris were gated out.</p><p>HepG2 cell apoptosis was analyzed using the annexin V/propidium iodide (PI) double staining method. HepG2 cells were plated at a density of 3x10 5 cells/well in a BD Falcon ® 12-well plate (BD Biosciences) and cultured in CIK cell-conditioned medium (CM CIK ), HepG2 cell-conditioned medium (CM control ) or a 1:1 mixture of the two conditioned media (thus, the percentages of CM CIK in the above media were 100, 0 and 50%, respectively). The pH of the media was adjusted to 6.5 or 7.4, correspondingly. After 48 h of incubation, the cells were collected, washed and resuspended in PBS. Then, annexin V-FITC and PI (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) were added to the cells, which were incubated at 4˚C for 20 min prior to being subjected to flow cytometer analysis. All the experiments were performed in triplicate.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.</head><p>The MTT colorimetric assay was used to determine the cytotoxic activity of CIK cells against HepG2 cells in vitro <ref type="bibr" target="#b14">(15)</ref>. The CIK cells [effector (E) cells] and the HepG2 cells [target (T) cells] were co-cultured in a 96-well plate with medium at pH 6.5 or 7.4. The ratios of CIK and HepG2 cells (E/T ratio) were set as 10:1, 20:1, 40:1 and 80:1. In addition, E cells or T cells alone were used as controls. The MTT assay was performed 20 h later to evaluate the cell viability, and the optical density (OD) values were measured at 570 nm. The assays were conducted in triplicate. The cytotoxic activity was calculated as follows:</p><formula xml:id="formula_0">Cytotoxic activity (%) = [1-(OD E+T -OD E )/OD T ] x 100%.</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fluorescence assay of cytotoxic effects of CIK cells on</head><p>HepG2-luc cells. HepG2-luc cells were co-cultured with CIK cells or in CM CIK at pH 6.5 or 7.4 respectively. The viability of HepG2-luc cells was assessed fluorescently using the IVIS ® Spectrum in vivo imaging system (Caliper Life Sciences; Perki-nElmer, Inc., Waltham, MA, USA). In co-culture, HepG2-luc cells were plated at a density of 8,000 cells/well into a BD Falcon ® 96-well plate (BD Biosciences), and CIK cells were then added to the 96-well plate at E/T ratios of 0:1, 10:1, 20:1, 40:1 and 80:1. In culture with CM CIK , HepG2-luc cells were plated at a density of 1,500 cells/well in a BD Falcon ® 96-well plate (BD Biosciences) with medium containing 0, 25, 50, 75 and 100% CM CIK . The assays were performed in triplicate. After 20 h of co-culture or 48 h of culture in CM CIK , 0.15 mg/ml D-luciferin was added into each well, and the luminescence activity (LA) was measured after additional 5-min incubation. Based on the LA values, the cytotoxicities of CIK cells were calculated according to the following formula: CIK cytotoxicity (%) = [(LA 0:1 -LA x:1 )/LA 0:1 ] x 100%, where LA 0:1 is the LA of HepG2-luc cells cultured in the absence of CIK cells, and LA x:1 is a variable that refers to the LA of HepG2-luc cells co-cultured with 10, 20, 40 or 80-fold CIK cells. The cytotoxicities present in the CM CIK were calculated according to the following formula: CM CIK cytotoxicity (%) = [(LA 0 -LA y )/LA 0 ] x 100%, where LA is the LA of the HepG2-luc cells, LA 0 is the LA of HepG2-luc cells cultured in the absence of CM CIK , and LA y is a variable that represents the LA of HepG2-luc cells cultured with 25, 50, 75 and 100% CM CIK.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Xenograf t assay.</head><p>A total of 20 female nude mice (6-8 weeks-old) were purchased from the Animal Experiment Center of Wuhan University (Wuhan, China). All mice were maintained in the Animal Experiment Center of the Hubei University of Medicine (Shiyan, China) at a controlled temperature and humidity, under a 12-h light/dark cycle, with ad libitum access to sterile food and water. The present study was performed with the approval of the Hubei University of Medicine ethical committee, and all the experiments were performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. In order to eradicate residual NK cells, the nude mice were administered 200 cGy of whole body irradiation and subcutaneously injected with 1x10 7 HepG2-luc cells. Subsequently, the mice were randomly divided into four groups according to the different treatments received: i) CIK cells injection plus oral administration of NaHCO 3 ; ii) CIK cells injection plus drinking water feeding; iii) normal saline injection plus oral administration of NaHCO 3 ; and iv) normal saline injection plus drinking water feeding (which served as control). CIK cells (1.5x10 7 cells/injection) or an equivalent volume of normal saline were intravenously injected in the mice through their tail veins on days 0, 7, 14, 21 and 28, while NaHCO 3 (200 mmol/l) or drinking water feeding were conducted on a daily basis. The LA of the tumors was monitored and measured with the IVIS ® Spectrum in vivo imaging system on days 0, 10, 20 and 30. The mice were sacrificed on day 30, and the tumor weights were measured.</p><p>Immunohistochemical analysis. The grafted tumor masses were fixed in 10% formalin, embedded in paraffin and sectioned with a thickness of 3 µm for immunohistochemical studies. Rabbit anti-human CD3 polyclonal antibody (cat. no. ab828; dilution, 1:50; Abcam, Cambridge, MA, USA) and mouse anti-human perforin monoclonal antibody (cat. no. ab47225; dilution, 1:50; Abcam) were used for immunostaining. Horseradish peroxidase-conjugated goat anti-rabbit (cat. no. ab6721; dilution, 1:1,000; Abcam) and goat anti-mouse (cat. no. ab6789; dilution, 1:1,000; Abcam) secondary antibodies were used for detection of the primary antibodies. All procedures were conducted according to the manufacturer's protocol. Images of the sections were acquired using an Olympus BX-60 microscope (Olympus Corporation, Tokyo, Japan) to determine the CD3 + and perforin + cell densities. The number of positive cells was blindly counted in 10 randomly selected independent fields (0.16 mm 2 at x400 magnification) for each section by two independent observers. Statistical analysis. Differences between groups were compared using analysis of variance, and the least significant difference test was used for multiple mean comparisons. P&lt;0.05 was considered to indicate a statistically significant difference. Statistical analysis was conducted using SPSS software v13.0 (SPSS Inc., Chicago, IL, USA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>Characteristics of CIK cells. The CIK cells induced with the method described above appeared regular, round, transparent and variable in size when observed under a microscope. They exhibited the ability of growth in suspension, and multiple characteristic cell clusters were formed ( <ref type="figure" target="#fig_1">Fig. 1A and B</ref>). After 14 days, the absolute number of human PBMCs cultured in the presence of IL-2 and anti-CD3 antibody increased by &gt;250-fold, from 5 million PBMCs to 1,300 million CIK cells. When the phenotypes of the cultured cell population were examined by fluorescence-activated cell sorting analysis, the cell population was observed to be composed of 92% CD3 + , 34% CD3 + CD56 + , 14% CD4 + and 73% CD8 + cells <ref type="figure" target="#fig_1">(Fig. 1C)</ref>.</p><p>The cytotoxic activity of CIK cells is significantly compromised under an acidic environment. Both the MTT assay </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>C B A</head><p>and the fluorescence assay demonstrated that CIK cells had a significantly higher cytotoxic activity against HepG2-luc cells in the medium with pH 7.4 than in the medium with pH 6.5. In the fluorescence assay, HepG2-luc cells were co-cultured with CIK cells at an E/T ratio of 0:1 10:1, 20:1, 40:1 or 80:1 at pH 6.5 or pH 7.4. The fluorescence intensities were significantly lower with pH 7.4 than with pH 6.5 for each paired cultures (P&lt;0.05; <ref type="figure" target="#fig_2">Fig. 2A and B)</ref>. The cytotoxic activity calculated based on the fluorescence intensity showed that the cytotoxicity of CIK cells were significantly higher with pH 7.4 than with pH 6.5 (P&lt;0.05; <ref type="figure" target="#fig_2">Fig. 2C</ref>).</p><p>In the MTT assay, 19, 38, 60 and 80% of HepG2-luc cells died when co-cultured with CIK cells at an E/T ratio of 10:1, 20:1, 40:1 and 80:1, respectively, in the medium with pH 7.4. However, only 4, 18, 30 and 45% of HepG2 cells died, respectively, at the same E/T ratios with pH 6.5 (P&lt;0.05; <ref type="figure" target="#fig_2">Fig. 2D</ref>). Highly consistent with the results of CIK cells in fluorescence assay, the CM CIK displayed stronger cytotoxicity activities in pH 7.4 condition than in pH 6.5 condition. The fluorescence intensities of HepG2-luc cells cultured in medium containing 50, 75 and 100% CM CIK were significantly lower with pH 7.4 than with pH 6.5 (P&lt;0.05; <ref type="figure" target="#fig_3">Fig. 3A and B)</ref>. The cytotoxicity of CM CIK in pH 7.4 condition was stronger than that in the pH 6.5 condition <ref type="figure" target="#fig_3">(Fig. 3C)</ref>.</p><p>In addition, the annexin V/PI double staining method was used to determine the percentage of cells that exhibited apoptosis and necrosis ( <ref type="figure" target="#fig_4">Fig. 4)</ref>. At a CM ratio of 50%, the CM CIK -induced apoptosis and necrosis in pH 6.5 and pH 7.4 medium were 15 and 26%, respectively. Furthermore, at a CM CIK ratio of 100%, the percentage of apoptosis and necrosis in pH-6.5 and pH-7.4 medium were 25 and 45%, respectively. These results indicated that the acidic environment inhibits the antitumor activity of CIK cells.</p><p>The activity of CIK cells against HCC is enhanced by NaHCO 3 feeding in nude mice. In order to further investigate whether NaHCO 3 treatment would enhance the antitumor activity of CIK therapy in vivo, HepG2-luc carcinoma-bearing nude mice were grouped and treated as above described. Nude mice were selected due to their lack of cellular immunity <ref type="bibr" target="#b15">(16)</ref>. The results revealed that there was no difference between the NaHCO 3 feeding group and the control group in terms of luminescence intensities from the tumors. The luminescence intensities of the tumors in the CIK group were significantly reduced compared with those in the control group, while those in the CIK plus NaHCO 3 feeding group were also significantly reduced compared with those in the CIK group ( <ref type="figure" target="#fig_5">Fig. 5A and B)</ref>. The tumor masses were isolated on day 30 <ref type="figure" target="#fig_5">(Fig. 5C</ref>) after grafted from each group, and the average weights of the tumors were consistent with the luminescence intensity analysis <ref type="figure" target="#fig_5">(Fig. 5D</ref>).   revealed that there was significantly more accumulation of CD3 + T lymphocytes and perforin in tumor tissue treated with CIK cells plus NaHCO 3 compared with tumor tissue treated with CIK cells alone <ref type="figure">(Fig. 6</ref>). There were almost no accumulation of CD3 + T lymphocytes or perforin in the tumor tissue from the other two groups. This result could explain why tumor growth was remarkably suppressed in the CIK+NaHCO 3 group.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>The acidic pH of the extracellular environment has a direct influence on a broad range of immunological functions <ref type="bibr" target="#b17">(18)</ref>. Previous studies on polymorphonuclear leukocytes demonstrate that this acidic pH mainly causes inhibition of chemotaxis, respiratory activity and bactericidal capacity <ref type="bibr" target="#b18">(19,</ref><ref type="bibr" target="#b19">20)</ref>. Evidence of impaired lymphocyte cytotoxicity and proliferation at acidic pH is also beginning to emerge <ref type="bibr" target="#b20">(21)</ref>. In addition, clinical acidosis is accompanied by immunodeficiency <ref type="bibr" target="#b21">(22)</ref>. Furthermore, other evidence has suggested that acidic microenvironments may play a role during neoplastic growth and invasion <ref type="bibr" target="#b22">(23)</ref>. CIK cells are ex vivo-expanded T lymphocytes that share phenotypic and functional properties with both NK and T cells <ref type="bibr" target="#b23">(24)</ref>. In view of the conclusions of previous studies, it is reasonable for us to infer that acidic microenvironments of solid tumors will affect the antitumor activity of CIK cells. Based on the mechanism underlying the antitumor effects of CIK cells, including the fact that CIK cells bind to T cells, form cellular conjugates with tumor cells and secrete a large number of cytotoxic cytoplasmic granules that are cytolytic to T cells <ref type="bibr" target="#b24">(25)</ref>, and the fact that CIK cells secrete a number of cytokines (including IFN-γ, IL-2 and tumor necrosis factor) that attack tumor cells <ref type="bibr" target="#b25">(26)</ref>, the present study compared the antitumor activities of CIK cells or CM CIK against HCC at pH 6.5 and 7.4. The results revealed that the antitumor activities of both CIK cells and CM CIK against HepG2 cells were significantly compromised under an acidic environment, with 35 and 25% reduction in cytotoxicity and tumor inhibition, respectively. These results strongly suggested that neutralization of the acidic environment in the tumor tissue should be equally important as the CIK cell therapy itself. CIK cells would not be fully active unless the acidic environment in tumor tissue is neutralized.</p><p>Previous experimental and mathematical models have successfully demonstrated that it is possible to upregulate the pHe of tumors with little effect on systemic pH by chronic administration of sodium bicarbonate <ref type="bibr" target="#b26">(27,</ref><ref type="bibr" target="#b27">28)</ref>. In addition, recent studies documented that oral administration of HCO 3 could actually inhibit tumor metastasis in prostate, breast and colon cancer cell line-derived tumors <ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref><ref type="bibr" target="#b30">(31)</ref>. This apparently occurred by reducing the extracellular acidity of the  <ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref><ref type="bibr" target="#b30">(31)</ref>. Previous findings suggested that certain enzymes such as cathepsins and matrix metalloproteases, which are involved in tumor invasion, were inhibited by alkalinization <ref type="bibr" target="#b31">(32)</ref>. In the present study, oral administration of NaHCO 3 was combined with CIK cell therapy in HCC-bearing nude mice to investigate whether NaHCO 3 could enhance the antitumor activity of CIK cells against HCC. The present data revealed a remarkable synergy between oral administration of NaHCO 3 and CIK cell therapy in treating grafted HepG2-luc carcinomas in nude mice, suggesting that oral NaHCO 3 administration may be sufficient to reduce the acidity of the tumor microenvironment, eventually enhancing the efficacy of CIK cell therapy. These findings and the in vitro results could explain one of the reasons why tumor cells thrive in the acidic environment, that is, due to the fact that the immune system is compromised in the acidic environment, thus facilitating the survival of tumor cells. Notably, oral administration of NaHCO 3 alone failed to inhibit the growth of the tumor in nude mice. This result was consistent with a previous study <ref type="bibr" target="#b27">(28)</ref>, in which NaHCO 3 administration was observed to have no effect on the growth of primary tumors in severe combined immunodeficiency mice. Thus, although NaHCO 3 inhibits spontaneous metastases by attenuating the function of certain enzymes, without the immune system, NaHCO 3 is unable to inhibit the primary tumor growth. However, this is not the true situation of the patients with tumors in the clinic, since the majority of these patients are immunologically intact <ref type="bibr" target="#b32">(33)</ref>. Therefore, even without receiving any immunotherapy such as CIK cell therapy, it would be beneficial for these patients to ingest alkaline food or drinks, since it may aid the T lymphocytes to fight against the tumor cells in their bodies. The present immunohistochemical studies on the tumor tissue from each group revealed a significantly augmented number of CD3 + T lymphocytes infiltrating into the tumor mass when NaHCO 3 feeding was combined with CIK cell therapy, compared with CIK cell therapy alone. In addition, the perforin secreted by T lymphocytes, which is important in killing T cells, was also abundantly detected by immunohistochemistry. These results suggest that the acidic environment appeared to prevent CIK cells from migrating into the tumor tissue, which may partially explain why immune cells such as CIK cells could not function well in an acidic environment. However, there may be other mechanisms involved, such as the acidic environment inhibiting the cytokine secretion of CIK cells, thus compromising their binding ability to the T cells. Further studies to explore the exact molecular mechanisms are warranted.</p><p>In summary, both the in vitro and in vivo experiments of the present study demonstrated that the antitumor activities of CIK cells against HepG2 cells were significantly enhanced under alkaline or relatively less acidic environments, although the molecular mechanism involved require to be further investigated. The present results have provided novel insights for oncologists to treat their cancer patients, particularly when immunotherapy is considered. <ref type="figure">Figure 6</ref>. Immunohistochemical study. Sections were prepared from the tumors isolated from the mice in the four different treatment groups on day 30 after HepG2-luc cells were injected into mice. (A) Immunostaining with anti-CD3 and anti-perforin antibodies revealed that there was more infiltration of T lymphocytes in the CIK+NaHCO 3 group than in the CIK only group. A total of 10 individual microscopic fields (0.16 mm 2 ; magnification, x400; scale bar, 25 µm) around the apoptotic areas were randomly selected to count the positive cells for (B) CD3 and (C) perforin, and the average numbers were summarized in a histogram (boxes, 75% percentile; lines, median; bars, standard deviation). * P&lt;0.05 in t test. CIK, cytokine-induced killer; CON, control; CD, cluster of differentiation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>C B</head><p>A the Science and Technology Department of Hubei Province (Wuhan, China; grant no. 2014CFA068) and the Science and Technology Department of Shiyan City (Shiyan, China; grant no. 16Y01).</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>Flow cytometry. A set of conjugated monoclonal antibodies (BD Biosciences, Franklin Lakes, NJ, USA), including anti-CD3-fluorescein isothiocyanate (FITC; cat. no. 561806; dilution, 1:20) as a T-cell marker, anti-CD4-phycoerythrin (PE; cat. no. 565999; dilution, 1:20) as a helper T-cell marker, anti-CD8-PE (cat. no. 561950; dilution, 1:20) as a cytotoxic T-cell marker and anti-CD56-PE (cat. no. 561903; dilution, 1:20) as a natural killer (NK) cell-marker, were used to define the phenotypes of CIK cells. In total, 1x10</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .</head><label>1</label><figDesc>Characterization of CIK cells. (A) Morphology of CIK cells under a phase-contrast microscope after 10 days of induction (magnification, x200). (B) A cluster of CIK cells were observed under a phase-contrast microscope (magnification, x200). (C) Flow cytometry analysis revealed that the percentages of CD8 + , CD4 + and CD3 + CD56 + cells were 73, 14 and 34%, respectively. CIK, cytokine-induced killer; CD, cluster of differentiation.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 .A</head><label>2</label><figDesc>Cytotoxicity of cytokine-induced killer cells against HepG2-luc cells under alkaline and acidic environments. (A-C) Fluorescence assay. (A) Fluorescence images were captured at 0 and 20 h. (B) The fluorescence activities measured after 20 h of co-culture decreased in an alkaline environment, while the E/T ratios (C) and the percentages of dead HepG2-luc cells increased. These results were highly consistent with the (D) 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay results. All the experiments were performed in triplicate. Error bars indicate the mean ± standard deviation. * P&lt;0.05, ** P&lt;0.01 in t test. E, effector cells; T, target cells; luc, luciferase.NaHCO 3 enhances the infiltration of CIK cells within the tumor tissue. Since CD3 + T lymphocytes are the main components of CIK cells and perforin is important in the antitumor effects of CIK cells<ref type="bibr" target="#b16">(17)</ref>, an immunohistochemical study was further performed on the excised tumor tissue with anti-CD3 and anti-perforin antibodies. The results</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 .</head><label>3</label><figDesc>Cytotoxicity of CM CIK against HepG2-luc cells under alkaline and acidic environments. HepG2-luc cells were cultured with different ratios of CM CIK at pH 6.5 and 7.4. (A) Fluorescence images were captured at 0 and 48 h. (B) Luciferase activities were measured at 48 h. (C) The percentages of dead HepG2-luc cells were calculated based on their luminescence activity at 48 h. The experiment was performed in triplicate. Error bars indicate the mean ±standard deviation. * P&lt;0.05 in t test. CM CIK , CIK cell-conditioned medium; CIK, cytokine-induced killer; luc, luciferase.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4 .</head><label>4</label><figDesc>Apoptosis and necrosis analysis of HepG2 cells cultured with CM CIK by annexin V/PI staining. Increased apoptosis and necrosis in an alkaline environment were observed when the proportions of CM CIK were 50 and 100%. (A) Flow cytometry assay. (B) Histogram comparing the percentages of apoptosis and necrosis of HepG2 cells at pH 6.5 and 7.4. The experiment was performed in triplicate. Error bars indicate the mean ± standard deviation. * P&lt;0.05, ** P&lt;0.01 in t test. CM CIK , CIK cell-conditioned medium; CIK, cytokine-induced killer; PI, propidium iodide.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 5 .</head><label>5</label><figDesc>Xenograft experiments. (A) In vivo fluorescence images of HepG2-luc-derived tumors of nude mice from four different experimental groups. (B) Histogram revealing that the fluorescence activities were reduced in the CIK+NaHCO 3 group. Each experimental group was composed of 5 mice. Error bars indicate the mean ±SD. * P&lt;0.05, ** P&lt;0.01 in t test. (C) Size of the tumor mass from the mice in the four different experimental groups. (D) Histogram revealing that the average weight of the tumor mass was significantly reduced in the CIK+NaHCO 3 group. Error bars indicate the mean ± SD. * P&lt;0.05 in t test. ROI, regions of interest; CIK, cytokine-induced killer; CON, control; luc, luciferase; SD, standard deviation. tumors, in the absence of changes in the pH of the blood or normal tissues</figDesc></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p>The present study was supported by grants from the Ministry of Education of China (Beijing, China; grant no. 20151092900),</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hashem</forename><forename type="middle">B</forename><surname>El-Serag</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2011.12.061</idno>
		<idno type="PMID">22537432</idno>
		<idno type="PMCID">PMC3338949</idno>
		<idno>1264.e1-1273.e1</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3338949?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<title level="j" type="abbrev">Gastroenterology</title>
		<idno type="ISSN">0016-5085</idno>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1264" to="1273.e1" />
			<date type="published" when="2012-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The Efficacy and Safety of Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cell Therapy in Combination with TACE-Predominant Minimally-Invasive Treatment for</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yingying</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yanming</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yue</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yangyu</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wenwang</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guang</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Changgui</forename><surname>Kou</surname></persName>
		</author>
		<idno type="DOI">10.7754/clin.lab.2015.150804</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical Laboratory</title>
		<title level="j" type="abbrev">Clin. Lab.</title>
		<idno type="ISSN">1433-6510</idno>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">04/2016</biblScope>
			<biblScope unit="page" from="599" to="608" />
			<date type="published" when="2016" />
			<publisher>Clinical Laboratory Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lihong</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jiali</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xuejing</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yanjie</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jingxiu</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yan</forename><surname>Pang</surname></persName>
		</author>
		<idno type="DOI">10.3892/mco.2015.660</idno>
		<idno type="PMID">26870371</idno>
		<idno type="PMCID">PMC4727101</idno>
		<ptr type="open-access" target="http://www.spandidos-publications.com/10.3892/mco.2015.660/download" />
	</analytic>
	<monogr>
		<title level="j">Molecular and Clinical Oncology</title>
		<idno type="ISSN">2049-9450</idno>
		<idno type="ISSNe">2049-9469</idno>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="129" to="133" />
			<date type="published" when="2015-10-23" />
			<publisher>Spandidos Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">G H</forename><surname>Schmidt-Wolf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Finke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Trojaneck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Denkena</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Lefterova</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Schwella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H-G</forename><surname>Heuft</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Prange</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Korte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Takeya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Dorbic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Neubauer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Wittig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Huhn</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.bjc.6690800</idno>
		<idno type="PMID">10576658</idno>
		<idno type="PMCID">PMC2362953</idno>
		<ptr type="open-access" target="https://www.nature.com/articles/6690800.pdf" />
	</analytic>
	<monogr>
		<title level="j">British Journal of Cancer</title>
		<title level="j" type="abbrev">Br J Cancer</title>
		<idno type="ISSN">0007-0920</idno>
		<idno type="ISSNe">1532-1827</idno>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1009" to="1016" />
			<date type="published" when="1999-10-29" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eva</forename><surname>Rettinger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vida</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hermann</forename><surname>Kreyenberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andreas</forename><surname>Volk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Selim</forename><surname>Kuçi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andre</forename><surname>Willasch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ewa</forename><surname>Koscielniak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Simone</forename><surname>Fulda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Winfried</forename><forename type="middle">S</forename><surname>Wels</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Halvard</forename><surname>Boenig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><surname>Klingebiel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><surname>Bader</surname></persName>
		</author>
		<idno type="DOI">10.3389/fonc.2012.00032</idno>
		<idno type="PMID">22655268</idno>
		<idno type="PMCID">PMC3356002</idno>
		<ptr type="open-access" target="https://www.frontiersin.org/articles/10.3389/fonc.2012.00032/pdf" />
	</analytic>
	<monogr>
		<title level="j">Frontiers in Oncology</title>
		<title level="j" type="abbrev">Front. Oncol.</title>
		<idno type="ISSNe">2234-943X</idno>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">32</biblScope>
			<date type="published" when="2012" />
			<publisher>Frontiers Media SA</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiang</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">T</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">Z</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">B</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.3748/wjg.v17.i25.3002</idno>
		<idno type="PMID">21799646</idno>
		<idno type="PMCID">PMC3132251</idno>
	</analytic>
	<monogr>
		<title level="j">World Journal of Gastroenterology</title>
		<title level="j" type="abbrev">WJG</title>
		<idno type="ISSN">1007-9327</idno>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page">3002</biblScope>
			<date type="published" when="2011" />
			<publisher>Baishideng Publishing Group Inc.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Danhong</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bin</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Haiyan</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guoliang</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Qiong</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jinchao</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Li</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hu</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2407-14-251</idno>
		<idno type="PMID">24720900</idno>
		<idno type="PMCID">PMC3997215</idno>
		<ptr type="open-access" target="https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-14-251" />
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<title level="j" type="abbrev">BMC Cancer</title>
		<idno type="ISSNe">1471-2407</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">251</biblScope>
			<date type="published" when="2014-04-10" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Adoptive Immunotherapy in Postoperative Hepatocellular Carcinoma: A Systemic Review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Feng</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xinji</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hui</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tao</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Feng</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rongxi</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Long</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jiamei</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jia</forename><surname>He</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0042879</idno>
		<idno type="PMID">22916174</idno>
		<idno type="PMCID">PMC3419734</idno>
		<ptr type="open-access" target="https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0042879&amp;type=printable" />
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<title level="j" type="abbrev">PLoS ONE</title>
		<idno type="ISSNe">1932-6203</idno>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">e42879</biblScope>
			<date type="published" when="2012-08-15" />
			<publisher>Public Library of Science (PLoS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Cancer Cell Metabolism: One Hallmark, Many Faces</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jason</forename><forename type="middle">R</forename><surname>Cantor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">M</forename><surname>Sabatini</surname></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.cd-12-0345</idno>
		<idno type="PMID">23009760</idno>
		<idno type="PMCID">PMC3491070</idno>
		<ptr type="open-access" target="https://cancerdiscovery.aacrjournals.org/content/candisc/2/10/881.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Discovery</title>
		<title level="j" type="abbrev">Cancer Discovery</title>
		<idno type="ISSN">2159-8274</idno>
		<idno type="ISSNe">2159-8290</idno>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="881" to="898" />
			<date type="published" when="2012-09-25" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Andersen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M A</forename><surname>Moreira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">F</forename><surname>Pedersen</surname></persName>
		</author>
		<idno type="DOI">10.1098/rstb.2013.0098</idno>
		<idno type="PMID">24493746</idno>
		<idno type="PMCID">PMC3917352</idno>
		<ptr type="open-access" target="https://royalsocietypublishing.org/doi/pdf/10.1098/rstb.2013.0098" />
	</analytic>
	<monogr>
		<title level="j">Philosophical Transactions of the Royal Society B: Biological Sciences</title>
		<title level="j" type="abbrev">Philosophical Transactions of the Royal Society B: Biological Sciences</title>
		<idno type="ISSN">0962-8436</idno>
		<idno type="ISSNe">1471-2970</idno>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="issue">1638</biblScope>
			<biblScope unit="page" from="20130098" to="20130098" />
			<date type="published" when="2014-02-03" />
			<publisher>The Royal Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>G A L La G H E R Fa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Ket T U N E N M I</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Se</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">E</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Ardenkjaer-Larsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zandt</forename><surname>Ri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">R</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Golman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">H</forename><surname>Lerche</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">M</forename><surname>Brindle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">453</biblScope>
			<biblScope unit="page" from="940" to="943" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Acidic Extracellular pH Promotes Experimental Metastasis of Human Melanoma Cells in Athymic Nude Mice</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Einar</forename><forename type="middle">K</forename><surname>Rofstad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Berit</forename><surname>Mathiesen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kristil</forename><surname>Kindem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kanthi</forename><surname>Galappathi</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.can-06-0983</idno>
		<idno type="PMID">16818644</idno>
		<ptr type="open-access" target="http://cancerres.aacrjournals.org/content/66/13/6699.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<title level="j" type="abbrev">Cancer Res</title>
		<idno type="ISSN">0008-5472</idno>
		<idno type="ISSNe">1538-7445</idno>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="6699" to="6707" />
			<date type="published" when="2006-07-01" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Dysregulated pH in tumor microenvironment checkmates cancer therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Barar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Omidi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioimpacts</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="149" to="162" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">V-ATPase inhibition overcomes trastuzumab resistance in breast cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karin</forename><surname>Von Schwarzenberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tamás</forename><surname>Lajtos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Làszló</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rolf</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">György</forename><surname>Vereb</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Angelika</forename><forename type="middle">M</forename><surname>Vollmar</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.molonc.2013.08.011</idno>
		<idno type="PMID">24055142</idno>
		<idno type="PMCID">PMC5528506</idno>
	</analytic>
	<monogr>
		<title level="j">Molecular Oncology</title>
		<idno type="ISSN">1574-7891</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="9" to="19" />
			<date type="published" when="2013-09-05" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">MTT colorimetric assay for testing macrophage cytotoxic activity in vitro</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mario</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><forename type="middle">Chiara</forename><surname>Fornasiero</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><forename type="middle">Maria</forename><surname>Isetta</surname></persName>
		</author>
		<idno type="DOI">10.1016/0022-1759(90)90187-z</idno>
		<idno type="PMID">2391427</idno>
		<idno type="PII">0022-1759(90)90187-Z</idno>
		<idno type="ark">ark:/67375/6H6-5X0CNQ2M-B</idno>
		<idno type="istexId">4E18ED9E821ACAA35D687D7BA256BF4364880537</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Immunological Methods</title>
		<title level="j" type="abbrev">Journal of Immunological Methods</title>
		<idno type="ISSN">0022-1759</idno>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="165" to="172" />
			<date type="published" when="1990-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Prominent IL-12 Production and Tumor Reduction in Athymic Nude Mice after Toxoplasma gondii Lysate Antigen Treatment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyoung-Ho</forename><surname>Pyo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bong-Kwang</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chun-Feng</forename><surname>Xin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">You-Won</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong-Yil</forename><surname>Chai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eun-Hee</forename><surname>Shin</surname></persName>
		</author>
		<idno type="DOI">10.3347/kjp.2014.52.6.605</idno>
		<idno type="PMID">25548411</idno>
		<idno type="PMCID">PMC4277022</idno>
	</analytic>
	<monogr>
		<title level="j">The Korean Journal of Parasitology</title>
		<title level="j" type="abbrev">Korean J Parasitol</title>
		<idno type="ISSNe">1738-0006</idno>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="605" to="612" />
			<date type="published" when="2014-12-23" />
			<publisher>Korean Society for Parasitology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Cholangiocarcinoma-derived exosomes inhibit the antitumor activity of cytokine-induced killer cells by down-regulating the secretion of tumor necrosis factor-α and perforin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jiong-Huang</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian-Yang</forename><surname>Xiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guo-Ping</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Li-Ping</forename><surname>Cao</surname></persName>
		</author>
		<idno type="DOI">10.1631/jzus.b1500266</idno>
		<idno type="PMID">27381730</idno>
		<idno type="PMCID">PMC4940629</idno>
		<ptr type="open-access" target="https://link.springer.com/content/pdf/10.1631/jzus.B1500266.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Zhejiang University-SCIENCE B</title>
		<title level="j" type="abbrev">J. Zhejiang Univ. Sci. B</title>
		<idno type="ISSN">1673-1581</idno>
		<idno type="ISSNe">1862-1783</idno>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="537" to="544" />
			<date type="published" when="2016-07" />
			<publisher>Zhejiang University Press</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The effects of extracellular pH on immune function</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Lardner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Leukoc Biol</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="522" to="530" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Neutrophil migration under agarose: Stimulation by lowered medium pH and osmolality</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Rabinovich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Destefano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Dziezanowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Reticuloendothel Soc</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="189" to="200" />
			<date type="published" when="1980" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">pH Changes Observed in the Inflamed Gingival Crevice Modulate Human Polymorphonuclear Leukocyte Activation In Vitro</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Binnaz</forename><surname>Leblebicioglu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jun</forename><forename type="middle">S</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anthony</forename><forename type="middle">C</forename><surname>Cario</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">Michael</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">D</forename><surname>Walters</surname></persName>
		</author>
		<idno type="DOI">10.1902/jop.1996.67.5.472</idno>
		<idno type="PMID">8724704</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Periodontology</title>
		<title level="j" type="abbrev">Journal of Periodontology</title>
		<idno type="ISSN">0022-3492</idno>
		<idno type="ISSNe">1943-3670</idno>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="472" to="477" />
			<date type="published" when="1996-05" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Influence of tumour physico-chemical conditions on interleukin-2-stimulated lymphocyte proliferation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">A</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">L</forename><surname>Juneau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Masserant</surname></persName>
		</author>
		<idno type="DOI">10.1038/bjc.1992.326</idno>
		<idno type="PMID">1419598</idno>
		<idno type="PMCID">PMC1977437</idno>
		<ptr type="open-access" target="https://www.nature.com/articles/bjc1992326.pdf" />
	</analytic>
	<monogr>
		<title level="j">British Journal of Cancer</title>
		<title level="j" type="abbrev">Br J Cancer</title>
		<idno type="ISSN">0007-0920</idno>
		<idno type="ISSNe">1532-1827</idno>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="619" to="622" />
			<date type="published" when="1992-10" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Science review: Extracellular acidosis and the immune response: Clinical and physiologic implications</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Kellum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Care</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="331" to="336" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Implications of Acidic Tumor Microenvironment for Neoplastic Growth and Cancer Treatment: A Computer Analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Kraus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bernhard</forename><surname>Wolf</surname></persName>
		</author>
		<idno type="DOI">10.1159/000217977</idno>
	</analytic>
	<monogr>
		<title level="j">Tumor Biology</title>
		<title level="j" type="abbrev">Tumor Biol</title>
		<idno type="ISSN">1010-4283</idno>
		<idno type="ISSNe">1423-0380</idno>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="133" to="154" />
			<date type="published" when="1996" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Nishimura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Beilhack</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Zeiser</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Olson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">I</forename><surname>Sega</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Karimi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">S</forename><surname>Negrin</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2007-06-092817</idno>
		<idno type="PMID">18565854</idno>
		<idno type="PMCID">PMC2532819</idno>
		<ptr type="open-access" target="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2532819/pdf" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<title level="j" type="abbrev">Blood</title>
		<idno type="ISSN">0006-4971</idno>
		<idno type="ISSNe">1528-0020</idno>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2563" to="2574" />
			<date type="published" when="2008-06-18" />
			<publisher>American Society of Hematology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Pievani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Borleri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Pende</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Moretta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Rambaldi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Golay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Introna</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2011-02-336321</idno>
		<idno type="PMID">21821703</idno>
		<ptr type="open-access" target="https://ashpublications.org/blood/article-pdf/118/12/3301/1340977/zh803811003301.pdf" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<title level="j" type="abbrev">Blood</title>
		<idno type="ISSN">0006-4971</idno>
		<idno type="ISSNe">1528-0020</idno>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3301" to="3310" />
			<date type="published" when="2011-08-05" />
			<publisher>American Society of Hematology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">T-Bet mediated anti-neoplastic effects of dendritic cell-cytokine induced killer cells in vitro</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Miao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Run-Ming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Iran J Pediatr</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="43" to="51" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">A mathematical model of tumour and blood pHe regulation: The buffering system</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Natasha</forename><forename type="middle">K</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eamonn</forename><forename type="middle">A</forename><surname>Gaffney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">A</forename><surname>Gatenby</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">J</forename><surname>Gillies</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ian</forename><forename type="middle">F</forename><surname>Robey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philip</forename><forename type="middle">K</forename><surname>Maini</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.mbs.2010.12.002</idno>
		<idno type="PMID">21167185</idno>
		<idno type="PMCID">PMC3045481</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3045481?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Mathematical Biosciences</title>
		<title level="j" type="abbrev">Mathematical Biosciences</title>
		<idno type="ISSN">0025-5564</idno>
		<imprint>
			<biblScope unit="volume">230</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2011-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Bicarbonate Increases Tumor pH and Inhibits Spontaneous Metastases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">F</forename><surname>Robey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">K</forename><surname>Baggett</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">D</forename><surname>Kirkpatrick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Roe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Dosescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">F</forename><surname>Sloane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">I</forename><surname>Hashim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">L</forename><surname>Morse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Raghunand</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Gatenby</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Gillies</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.can-07-5575</idno>
		<idno type="PMID">19276390</idno>
		<idno type="PMCID">PMC2834485</idno>
		<ptr type="open-access" target="https://cancerres.aacrjournals.org/content/canres/69/6/2260.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<title level="j" type="abbrev">Cancer Research</title>
		<idno type="ISSN">0008-5472</idno>
		<idno type="ISSNe">1538-7445</idno>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2260" to="2268" />
			<date type="published" when="2009-03-10" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jonathan</forename><forename type="middle">W</forename><surname>Wojtkowiak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><surname>Verduzco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karla</forename><forename type="middle">J</forename><surname>Schramm</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">J</forename><surname>Gillies</surname></persName>
		</author>
		<idno type="DOI">10.1021/mp200292c</idno>
		<idno type="PMID">21981633</idno>
		<idno type="PMCID">PMC3230683</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3230683?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Molecular Pharmaceutics</title>
		<title level="j" type="abbrev">Mol. Pharmaceutics</title>
		<idno type="ISSN">1543-8384</idno>
		<idno type="ISSNe">1543-8392</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2032" to="2038" />
			<date type="published" when="2011-12-05" />
			<publisher>American Chemical Society (ACS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Acidity Generated by the Tumor Microenvironment Drives Local Invasion</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Estrella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Lloyd</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Wojtkowiak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">H</forename><surname>Cornnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ibrahim-Hashim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Balagurunathan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Rothberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">F</forename><surname>Sloane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Gatenby</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Gillies</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.can-12-2796</idno>
		<idno type="PMID">23288510</idno>
		<idno type="PMCID">PMC3594450</idno>
		<ptr type="open-access" target="https://cancerres.aacrjournals.org/content/canres/73/5/1524.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<title level="j" type="abbrev">Cancer Research</title>
		<idno type="ISSN">0008-5472</idno>
		<idno type="ISSNe">1538-7445</idno>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1524" to="1535" />
			<date type="published" when="2013-01-03" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">The Potential Role of Systemic Buffers in Reducing Intratumoral Extracellular pH and Acid-Mediated Invasion</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">S</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Yunes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Gillies</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Gatenby</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.can-08-2394</idno>
		<idno type="PMID">19276380</idno>
		<idno type="PMCID">PMC3718046</idno>
		<ptr type="open-access" target="http://cancerres.aacrjournals.org/content/69/6/2677.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<title level="j" type="abbrev">Cancer Research</title>
		<idno type="ISSN">0008-5472</idno>
		<idno type="ISSNe">1538-7445</idno>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2677" to="2684" />
			<date type="published" when="2009-03-10" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Investigating Mechanisms of Alkalinization for Reducing Primary Breast Tumor Invasion</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ian</forename><forename type="middle">F</forename><surname>Robey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lance</forename><forename type="middle">A</forename><surname>Nesbit</surname></persName>
		</author>
		<idno type="DOI">10.1155/2013/485196</idno>
		<idno type="PMID">23936808</idno>
		<idno type="PMCID">PMC3722989</idno>
		<ptr type="open-access" target="http://downloads.hindawi.com/journals/bmri/2013/485196.pdf" />
	</analytic>
	<monogr>
		<title level="j">BioMed Research International</title>
		<title level="j" type="abbrev">BioMed Research International</title>
		<idno type="ISSN">2314-6133</idno>
		<idno type="ISSNe">2314-6141</idno>
		<imprint>
			<biblScope unit="volume">2013</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2013" />
			<publisher>Hindawi Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">The Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hongjin</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fengcai</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lixin</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhixin</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhaohua</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peiwen</forename><surname>Lian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peng</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1177/1533034616659163</idno>
		<idno type="PMID">27436839</idno>
		<idno type="PMCID">PMC5665149</idno>
		<ptr type="open-access" target="https://journals.sagepub.com/doi/pdf/10.1177/1533034616659163" />
	</analytic>
	<monogr>
		<title level="j">Technology in Cancer Research &amp; Treatment</title>
		<title level="j" type="abbrev">Technol Cancer Res Treat</title>
		<idno type="ISSN">1533-0346</idno>
		<idno type="ISSNe">1533-0338</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="577" to="585" />
			<date type="published" when="2016-07-19" />
			<publisher>SAGE Publications</publisher>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
